Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Core Insights - Aclarion, Inc. has achieved a significant milestone with the second payer coverage of its Nociscan technology by Aviva in London, UK, enhancing access for patients suffering from chronic low back pain [1][2] - Aviva is one of the top four private medical insurers in the UK, holding approximately 14% of the private medical insurance market, which translates to around 1.2 million insured customers [2][3] - The collaboration with Aviva, alongside AXA, allows Nociscan to be accessible to approximately 45% of patients with private insurance in the Greater London area [2] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to assist physicians in diagnosing and treating patients [4] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine, providing critical insights for treatment optimization [4] Market Context - In the UK, self-pay and private medical insurance account for nearly 70% of private hospital revenues, indicating a growing trend in the adoption of private medical insurance [2] - The London Clinic has integrated Nociscan as a key decision support tool for diagnosing chronic low back pain, which affects up to one-third of the UK adult population annually [3]